

Virus Collection Using Gelatin Membrane Technology:

**The Sartorius AirPort MD8 Air Sampler**

Sartorius Stedim Biotech S.A.  
Z.I. Les Paluds  
Avenue de Jouques  
B.P. 1051  
13781 Aubagne - France

[www.sartorius-stedim.com](http://www.sartorius-stedim.com)

Goettingen, August 11, 2009 – Sartorius water-soluble gelatin membrane filters are suitable for collecting airborne viruses that cause respiratory illnesses, such as influenza viruses, which include the swine flu virus A (H1N1). This has been shown by studies already performed in 1990 and that are now regaining topicality because of the swine flu pandemic.

The **AirPort MD8** from Sartorius Stedim Biotech uses the gelatin membrane filter method applied in these virus collection studies as gelatin membrane filters have been proven to ensure reliable and accurate results. Among the advantages of the AirPort MD8 air sampler is its high recovery rate achieved for microorganisms and viruses. Organisms collected by air sampling can be cultivated on various culture media, and the solubility of the gelatin filter opens up many further applications, such combination with quick-test systems, quantitative collection of airborne viruses and measurement of extremely high microbe or virus concentrations.

Thanks to its rechargeable battery, the AirPort MD8 is portable, guarantees consistent performance by showing the level of battery power and is easy to clean. The four-language display, flexible settings of the air flow rate and sample volume as well as the option of calibrating the AirPort MD8 on site make this air sampler ideal for the pharmaceutical industry and for use in hospitals, environmental protection and in occupational safety.

**A Profile of Sartorius Stedim Biotech**

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next-generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions" on a daily basis.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs over 2,300 people, and in 2008 generated sales revenue of 368.0 million euros.

**Photo| Image File for Press Release:**

Image | Photo: The air sampler AirPort MD8 from Sartorius Stedim Biotech for collecting airborne microbes and viruses

---

**Contacts:**

Dominic Grone | Stephanie Sinagowitz; Sartorius Group Corporate Communications  
Sartorius Corporate Administration GmbH; 37070 Goettingen, Germany  
Phone: +49(0)551/ 308-3324 or -3684; fax: +49(0)551/ 308-3572;  
E-mail: [dominic.grone@sartorius.com](mailto:dominic.grone@sartorius.com); [stephanie.sinagowitz@sartorius.com](mailto:stephanie.sinagowitz@sartorius.com)  
<http://www.sartorius-stedim.com> Press Service: <http://www.sartorius.com/presse.html>